207 related articles for article (PubMed ID: 35113366)
21. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
22. Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept.
Decker DA; Higgins P; Hayes K; Bollinger C; Becker P; Wright D
BMC Musculoskelet Disord; 2020 Aug; 21(1):586. PubMed ID: 32867752
[TBL] [Abstract][Full Text] [Related]
23. Acthar® Gel (repository corticotropin injection) dose-response relationships in an animal model of epileptic spasms.
Le JT; Frost JD; Swann JW
Epilepsy Behav; 2021 Mar; 116():107786. PubMed ID: 33548914
[TBL] [Abstract][Full Text] [Related]
24. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
[TBL] [Abstract][Full Text] [Related]
25. Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies.
Patel A; Seely G; Aggarwal R
Case Rep Rheumatol; 2016; 2016():9068061. PubMed ID: 27642533
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
Clinicoecon Outcomes Res; 2023; 15():739-752. PubMed ID: 37868649
[TBL] [Abstract][Full Text] [Related]
27. Follow-up results of myositis patients treated with H. P. Acthar gel.
Saygin D; Oddis CV; Marder G; Moghadam-Kia S; Nandkumar P; Neiman N; Dzanko S; Koontz D; Aggarwal R
Rheumatology (Oxford); 2020 Oct; 59(10):2976-2981. PubMed ID: 32160301
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH
Poola N; Due B; Wright D; Brooks LR; Zaman F
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):502-515. PubMed ID: 34528408
[TBL] [Abstract][Full Text] [Related]
29. Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study.
Nguyen QD; Anesi SD; Chexal S; Chu DS; Dayani PN; Leng T; Meleth AD; Sallam AA; Sheppard JD; Silverstein SM; Toyos M; Wang RC; Foster CS
Acta Ophthalmol; 2021 Sep; 99(6):669-678. PubMed ID: 33751822
[TBL] [Abstract][Full Text] [Related]
30. A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States.
Nelson WW; Philbin MJ; Gallagher JR; Heap K; Carroll S; Wan GJ
Rheumatol Ther; 2017 Dec; 4(2):465-474. PubMed ID: 29071588
[TBL] [Abstract][Full Text] [Related]
31. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Front Neurol; 2020; 11():598496. PubMed ID: 33414758
[No Abstract] [Full Text] [Related]
32. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms.
Gold LS; Nazareth TA; Yu TC; Fry KR; Mahler NH; Rava A; Waltrip Ii RW; Hansen RN
Pediatric Health Med Ther; 2019; 10():195-207. PubMed ID: 32099512
[TBL] [Abstract][Full Text] [Related]
33. Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series.
Brown AN
Open Access Rheumatol; 2016; 8():97-102. PubMed ID: 27956846
[TBL] [Abstract][Full Text] [Related]
34. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
35. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome.
Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
Curr Med Res Opin; 2021 Mar; 37(3):431-441. PubMed ID: 33411573
[TBL] [Abstract][Full Text] [Related]
36. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
Toyos M; Toyos R; Jodoin B; Bunch R
Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
[TBL] [Abstract][Full Text] [Related]
37. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
38. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
[TBL] [Abstract][Full Text] [Related]
39. Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis.
Hayes K; Panaccio MP; Goel N; Fahim M
Rheumatol Ther; 2021 Mar; 8(1):327-346. PubMed ID: 33400194
[TBL] [Abstract][Full Text] [Related]
40. Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches.
Obi ON; Saketkoo LA; Russell AM; Baughman RP
Front Med (Lausanne); 2022; 9():991783. PubMed ID: 36314034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
